Impact of sex, age at onset, and anti-cN1A antibodies on sporadic inclusion body myositis

被引:0
|
作者
Yamashita, Satoshi [1 ,2 ]
Tawara, Nozomu [1 ]
Sugie, Kazuma [3 ]
Suzuki, Naoki [4 ]
Nishino, Ichizo [5 ]
Aoki, Masashi [4 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[2] Int Univ Hlth & Welf, Narita Hosp, Dept Neurol, 852 Hatakeda, Narita, Chiba 2868520, Japan
[3] Nara Med Univ, Sch Med, Dept Neurol, Kashihara, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Japan
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Japan
基金
日本学术振兴会;
关键词
Sporadic inclusion body myositis (IBM); Ages at onset; Disease duration; Gender; Cytoplasmic 5 '-nucleotidase 1 a autoantibody; CYTOSOLIC 5'-NUCLEOTIDASE 1A; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; AUTOANTIBODIES;
D O I
10.1016/j.jns.2024.123164
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Inclusion body myositis (IBM) is a progressive myopathy occurring in patients over 45 years of age, with heterogeneous and variable clinical features. This study aimed to determine the influence of autoantibodies, gender, and age of onset on the clinical features of IBM. Methods: Medical records and muscle histology findings of 570 participants with suspected IBM were reviewed. Various characteristics of patients who met the 2011 ENMC IBM diagnostic criteria were compared based on the presence of anti-cytosolic 5 '-nucleotidase 1 A (cN1A) autoantibodies, gender, age of onset, and disease duration. Results: Of the 353 patients who met the criteria, 41.6% were female. The mean age at onset was 64.6 +/- 9.3 years, and the mean duration from onset to diagnosis was 5.7 +/- 4.7 years. 196 of the 353 patients (55.5%) were positive for anti-cN1A autoantibodies and 157 were negative. Logistic regression showed that patients with anticN1A autoantibodies had a higher frequency of finger flexion weakness. Multiple regression showed that patients with later age of onset had shorter disease duration, lower BMI, and lower serum CK levels. Male patients had a higher frequency of onset with finger weakness and female patients had a lower BMI. Conclusion: Autoantibodies, gender, age of onset, and disease duration may influence the clinical presentation of IBM, highlighting the need for a precision medicine approach that considers these factors along with the underlying mechanisms of the disease.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis
    Koffman, BM
    Rugiero, M
    Dalakas, MC
    MUSCLE & NERVE, 1998, 21 (01) : 115 - 117
  • [22] ANT1 is reduced in sporadic inclusion body myositis
    E. Barca
    M. Aguennouz
    A. Mazzeo
    S. Messina
    A. Toscano
    G. L. Vita
    S. Portaro
    D. Parisi
    C. Rodolico
    Neurological Sciences, 2013, 34 : 217 - 224
  • [23] ANT1 is reduced in sporadic inclusion body myositis
    Barca, E.
    Aguennouz, M.
    Mazzeo, A.
    Messina, S.
    Toscano, A.
    Vita, G. L.
    Portaro, S.
    Parisi, D.
    Rodolico, C.
    NEUROLOGICAL SCIENCES, 2013, 34 (02) : 217 - 224
  • [24] Impact of a Ketogenic Diet on Sporadic Inclusion Body Myositis: A Case Study
    Phillips, Matthew C. L.
    Murtagh, Deborah K. J.
    Ziad, Fouzia
    Johnston, Samuel E.
    Moon, Ben G.
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [25] Sex hormone levels and response to androgen therapy in sporadic inclusion body myositis
    Acosta, J
    Herzog, A
    Rutkove, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 199 : S49 - S49
  • [26] AN UNUSUALLY EARLY ONSET AND FULMINANT COURSE OF SPORADIC INCLUSION BODY MYOSITIS: A CASE REPORT
    Walsh, Alison
    Rakocevic, Goran
    MUSCLE & NERVE, 2014, 50 (04) : 673 - 673
  • [27] Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms
    Mastaglia, F. L.
    Rojana-udomsart, A.
    James, I.
    Needham, M.
    Day, T. J.
    Kiers, L.
    Corbett, J. A.
    Saunders, A. M.
    Lutz, M. W.
    Roses, A. D.
    NEUROMUSCULAR DISORDERS, 2013, 23 (12) : 969 - 974
  • [28] TREX1 mutations are not associated with sporadic inclusion body myositis
    Cox, F. M.
    Boon, E. M. J.
    van der Lans, C. A. C.
    Bakker, E.
    Verschuuren, J. J. G. M.
    Badrising, U. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (08) : 1108 - 1109
  • [29] Anti-PM-Scl antibodies in a patient with inclusion body myositis
    Selva-O'Callaghan, A
    Mijares-Boeckh-Behrens, T
    Labrador-Horrillos, M
    Solans-Laque, R
    Grau-Junyent, JM
    Vilardell-Tarres, M
    RHEUMATOLOGY, 2003, 42 (08) : 1016 - 1018
  • [30] Pathomechanisms of Anti-Cytosolic 5′-Nucleotidase 1A Autoantibodies in Sporadic Inclusion Body Myositis
    Tawara, Nozomu
    Yamashita, Satoshi
    Zhang, Xiao
    Korogi, Mai
    Zhang, Ziwei
    Doki, Tsukasa
    Matsuo, Yoshimasa
    Nakane, Shunya
    Maeda, Yasushi
    Sugie, Kazuma
    Suzuki, Naoki
    Aoki, Masashi
    Ando, Yukio
    ANNALS OF NEUROLOGY, 2017, 81 (04) : 512 - 525